Space motion sickness: A common neurovestibular dysfunction in microgravity

Thais Russomano¹,²,³, Michele da Rosa²,³, Marlise A dos Santos¹

Abstract:
This article presents a review of the current findings related to neurovestibular physiology, aetiology, and proposed theories on space motion sickness (SMS) during acute and sustained exposure to microgravity. The review discusses the available treatment options including medication and nonpharmacological countermeasure methods that help to prevent the development of SMS in weightlessness. Ground-based simulations using virtual reality, flight simulations, and Barany's chairs can be applied to study SMS and demonstrate its signs and symptoms to space crew members. Space motion sickness has been observed in approximately 70% of astronauts within the first 72 h in microgravity, having in general an instantaneous onset of signs and symptoms. Stomach discomfort, nausea, vomiting, pallor, cold sweating, salivation, tachypnoea, belching, fatigue, drowsiness, and stress hormone release have been documented. This can have detrimental effects on the well-being of astronauts in the initial phase of a space mission. Mental and physical performance may be affected, jeopardizing operational procedures and mission safety.

Key Words:
Microgravity, neurology, space motion sickness, space neurovestibular physiology

Key Message:
Space motion sickness often occurs in astronauts during their acute and sustained exposure to microgravity, which may significantly jeopardize their operational preparedness. The physiological and etiopathological aspects of space motion sickness associated with weightlessness and the pharmacological and nonpharmacological countermeasures are being reviewed.

Historically, SMS was first reported as an operational issue in 1962 on board the spacecraft Vostok II, the second manned Soviet mission.[3] After reaching Earth’s orbit, Cosmonaut Titov experienced a period in which he felt as if he were flying upside-down, followed soon after by a period of dizziness associated with movement of his head. Approximately 6 h into the spaceflight, he exhibited the signs and symptoms of SMS.[3] Titov’s mission lasted only one day, but as flight durations increased with subsequent missions, it soon became more apparent that SMS posed a more prominent problem. No incidences of SMS were reported by astronauts in the pioneering NASA Mercury and Gemini manned spaceflight programs, with the first occurrences being described during the subsequent Apollo and Skylab missions.[5] This may be explained by the fact that the spacecraft first used were very small, limiting the movement of astronauts within the cabin and, therefore, decreasing the chances of experiencing SMS, as it would seem to present

Motion sickness is defined as the combination of signs and symptoms, including nausea, vomiting, sweating, lack of well-being, decreased mental and physical performance, disorientation, and drowsiness. These symptoms can occur with the introduction of a new type of real or virtual motion environment, as experienced when travelling in a car or on a boat, or when having a ride on an accelerative device, such as found in an entertainment park.

When a space traveller exposed to weightlessness during a mission in Earth’s orbit experiences this constellation of symptoms, it is referred to as Space Motion Sickness or SMS. The susceptibility of individuals to experiencing motion sickness or SMS depends on several factors. These include the initial sensitivity to motion, the rate of natural adaptation, and the ability to retain protective adaptation in the longer term.[11]
a close association between rapid head and body movements during microgravity exposure.[9]

SMS itself is described as the anomalous perceptual, sensory, sensorimotor, and autonomic reactions that, in general, develop during the very first phase of microgravity exposure.[6] Undoubtedly, there is similarity with the clinical presentation of terrestrial motion sickness, especially with regards to symptoms and time course of clinical development of this neurovestibular condition, in response to an environmental stimulus [Figure 1].

The common symptoms are malaise, anorexia or loss of appetite, reduced initiative, and irritability, stomach awareness, nausea, vomiting, headache, impaired concentration, lack of motivation, cold sweating, fatigue, increased respiratory rate, impaired mental and physical performance, disorientation, drowsiness, and lethargy.[4,5,7–9] Gastrointestinal symptoms in SMS appear minutes to hours after orbital insertion or in the first set of parabolas of a parabolic flight. The most common symptoms are usually nausea and vomiting, with the onset of vomiting sometimes occurring suddenly and without prodromal nausea. Belching, salivation, and flatulence can also accompany, while auscultation of the abdomen during SMS shows that bowel sounds and movement are either decreased or absent.[9]

In general, symptoms related to SMS (50% of cases being considered moderate-to-severe) during a space mission resolve after 3 days in microgravity, and post-flight recovery from this neurovestibular condition appears to occur quickly.[9] SMS is the most common clinical condition experienced by astronauts during the first three days of a spaceflight and can impact significantly on performance, affecting approximately 70% of the men and women who have flown in spacecraft or during the microgravity exposure provided by parabolic flights.[10–12]

The detrimental effect of this condition on astronaut functioning, behaviour, well-being and mood can pose additional concerns in relation to astronaut safety, especially if an extra-vehicular activity (EVA) were to be scheduled at the beginning of a space mission. For this reason, unless due to a specific emergency situation, the EVAs are not programmed to take place during the first few days of spaceflight, aimed at avoiding the potential negative effects of SMS, with the accompanying reduction in physical and mental performance. Nausea and vomiting, in particular, could lead to a life-threatening situation should an astronaut vomit whilst wearing an EVA suit.[13] Although it is recognised as one of the most frequent neurovestibular disturbances experienced during a spaceflight, the cause of space motion sickness is an important topic of discussion and is still not fully understood by the space medical and scientific communities.[12]

Physiological Mechanisms Associated with Space Motion Sickness

Two major mechanisms have been proposed to explain SMS: the fluid shift and sensory conflict theories. The microgravity of space appears to affect every single organ and body system of astronauts, in different intensities and manner, both during short- and long-term missions. The fluid shift theory suggests that there is a progressive displacement of fluid and blood from the lower to upper part of the body that starts with the exposure of an astronaut to microgravity. This process is completed within 7–10 days.[9,14,15] Initially, this headward shift increases the central fluid volume, cardiac size (around 20%) and cardiac output. It then leads to a negative fluid balance and reduction of 12–20% in the circulating blood volume,[16] which causes a decreased resting stroke volume of 10–20% and a reduced cardiac output, with an average reduction of 1.5L/min over the pre-flight values.[16,17] These changes are secondary to the reduction in circulating blood volume.[10]

This headward fluid shift is also associated with changes in the fluid of the vestibular system, subsequently altering receptor responses in the inner ear. Engorgement of the blood vessels surrounding the endolymphatic duct may restrict the flow of the endolymph sac, resulting in hydrops, or the pressure may act directly on the 8th nerve at the internal auditory meatus. This could then alter the responses of vestibular receptors, inducing the establishment of SMS. Several mechanisms have been proposed to explain how the headward fluid shift associated with microgravity may produce SMS. The headward fluid shift may change the angiotensin activity and produce SMS by altering hormonal or neurotransmitter balance in the chemoreceptor trigger zone, or it may alter the biomechanical properties of the vestibular system.[6,19]

Sensory Conflict Theory

The sensory conflict theory has been widely accepted as the primary cause of SMS during two crucial phases of a space mission—at the beginning and the end of an orbital flight. The three-dimensional human spatial orientation under Earth’s gravitational conditions is mainly based on sensory inputs that are sent to the central nervous system for interpretation. Therefore, the sensory-conflict theory advocates that space motion sickness must be a consequence of the rearrangement of the terrestrial gravity-related relationship between different inputs that are provided by the eyes, skin, joints, muscles, and especially vestibular receptors in the inner ear, when one is exposed to the microgravity environment of space. The interaction of all body systems, commonly used to orient ourselves in relation to the surrounding environment, become disrupted or compromised to some degree. This causes a sensory-motor disturbance that can lead to sensory conflict, which appears to constitute the basic mechanism underlying SMS, an illusion of self-motion associated with spatial disorientation.[10]

Head movements, however, especially in the pitch and roll planes, could be seen as the dominant provocative stimuli for the occurrence of SMS.[20] They result in discordant cues being transmitted to the central nervous system regions responsible for central integration of the semi-circular canals (angular acceleration) and the otolith organs (linear acceleration). These organs provide the relevant physiological information needed to maintain spatial orientation and promote the stabilization of eye and body movements.[12]

Further possible explanations which suggest that some form of anatomical and physiological changes of the vestibular system cause SMS are the otolith asymmetry and the otolith...
till-translation reinterpretation (OTTR) hypotheses. In the first, there is a minor asymmetry between the otolith system on either side of the head, which the brain adapts and compensates to from birth on Earth. However, this asymmetry can be exacerbated when an astronaut experiences the microgravity of space; the central nervous system becomes unable to properly interpret the signals sent by the otolith system and, therefore, the compensatory effect is lost. The latter theory suggests that the vestibular signals indicating the tilt become unnecessary when in microgravity. This leads to a reinterpretation of these inputs by the brain to indicate translation.

Fluid shift and sensory conflict, therefore, are the two major theories that attempt to explain why SMS is so prevalent during the first days of a spaceflight. However, many questions remain without answers, including their lack of predictive power, the inability to explain those situations in which sensory conflict exists without sickness, or the mechanisms behind the high prevalence of some symptoms of SMS, such as vomiting. Although the fluid-shift theory could be associated with sensory conflict, mechanisms exist whereby the cephalad fluid shift accompanying microgravity could bypass the classic vestibular inputs to induce vomiting. The susceptibility to provocative motion stimulation was not increased during head-down tilt.

Managing Space Motion Sickness

Space motion sickness is usually treated using pharmaceuticals, and although the drugs have undesirable side effects, they seem to totally or partially counteract SMS signs and symptoms in parabolic flights or during space missions, especially if the medication is given with other preventive methods. The use of different drugs in isolation or combination has been widely tested, but an ideal treatment for SMS has yet to be found. However, the high prevalence of SMS and the possibility of symptoms interfering with the operational activities required during space missions, has resulted in a general consensus that further research on the development of proper medical treatment and the use of countermeasures are mandatory.

Training devices and methods can be applied to familiarize astronauts and future space tourists with spatial disorientation and SMS. This equipment is also widely used for ground-based SMS studies with three main objectives—to have a better understanding of the underlying mechanisms involved, to test medications that can decrease or abolish symptoms, and to develop countermeasures to prevent the establishment of SMS during acute and chronic microgravity exposure. Virtual reality, flight simulators and rotatory chairs (Barany’s chair) have been widely used, either in isolation or in combination, to create a real or virtual motion environment capable of triggering the symptoms of SMS.

Histamine, acetylcholine, and noradrenaline are neurotransmitters that seem to be involved in the neural processes of motion sickness. This information helps with the selection of possible medication, in isolation or in combination that can be administered to either prevent or treat SMS, by abolishing or decreasing its symptoms. Pharmacological countermeasures have been well studied and many medications have been considered for preventing the occurrence of SMS during space missions or parabolic flights. Although, several drugs have been tested in-flight or during ground-based studies, few have been found to be effective and none can completely prevent the occurrence of signs and symptoms of motion sickness. Two of the many medications evaluated that demonstrate more promise as a prophylactic treatment are are scopolamine and prometazine.

Scopolamine, also known as either hyoscine or 6-phydroxyhyoscyamine, is a tropane alkaloid found in various solanaceous plants, especially in species of Datura, Scopolia, and Duboisia. Scopolamine presents a variety of biological activities and, therefore, has been used to treat seizures, vomiting and motion sickness. It also has undesirable effects, like drowsiness and performance decrement, particularly in tasks requiring continuous attention and memory storage of new information. This might affect the safety of astronauts during a space mission.

Oral scopolamine hydrobromide (ranging from 0.3 mg to 0.6 mg) is a drug commonly used to provide short-term protection against SMS, as it begins to act within 30 min to 1 hour and provides protection for around 4 hours. The use of a transdermal therapeutic scopolamine patch behind the ear 12 to 16 hours prior to requirement and delivering scopolamine into the blood for 72 hours has been proposed. Nonetheless, the transdermal method of delivering scopolamine is inappropriate for use during spaceflight, as an immediate relief of SMS symptoms is required. To counteract the known side effects of scopolamine, such as drowsiness, an amphetamine (5 mg to 10 mg orally) can be added, a combination commonly used in the pre-flight stage during the parabolic flight campaigns of the European Space Agency (ESA). The oral medication often interacts with food, different types of diets or fasting. Scopolamine associated with controlled diet has been shown to ameliorate the intensity and/or the number of symptoms experienced by volunteers during a ground-based study, in which rotation of a Barany’s chair was used to induce SMS. Although the scopolamine/amphetamine combination protocol has been used by ESA, oral administration of scopolamine is known to have variable absorption rates and a low oral bioavailability. These characteristics can become worse in the microgravity environment of space, which can cause alterations in the gastrointestinal system. Considerable numbers of studies have recently been performed to find a solution for overcoming these problems through the development of a new form of scopolamine dosage. Researchers have identified that intranasal scopolamine can provide an improved method of administration, as it is a quick-acting (15 min), non-invasive route of delivery. The first-passage metabolism is avoided, signifying the potential for enhanced efficacy at a lower dose, thus minimizing side-effects. Nowadays, an aqueous intranasal scopolamine spray (INSCOP) is available and is likely to be used by astronauts to prevent SMS.

In 2007, NASA advocated the use of 25 or 50 mg of intramuscular prometazine to prevent or decrease the symptoms of SMS. The pharmacodynamics of both medications have shown that scopolamine is a selective vestibular suppressor while prometazine is a global vestibular suppressor, resulting in a greater number of prometazine mediated-secondary effects,
which can cause more pronounced sedation and orthostatic hypotension.\textsuperscript{[8,10,29,32,33]}

**Conclusion**

The main functions of the neurovestibular system are spatial orientation, maintenance of balance, and stabilization of vision through the vestibular–ocular reflexes. Motion sickness is a syndrome that occurs when an individual is placed in a real or virtual moving environment, being called space motion sickness when it occurs during microgravity exposure. It is an extremely prevalent clinical condition seen during parabolic flights or space missions and can cause important detrimental effects on the well-being and performance of individuals, and, therefore, it is essential that the underlying neurovestibular mechanisms are better studied and understood on the ground and in space. There remains the need to further prevent or reduce the symptoms of SMS. Further research should aim to develop better non-pharmacological and pharmacological treatments.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Reason JT, Brand JJ. Motion Sickness. London: Academic press; 1975. p. 102, 135.
2. Lackner JR, Dixio P. Space motion sickness. Exp Brain Res 2006;175:377-99.
3. Souvestre PA, Blaber AP, Landrock CK. Space motion sickness: The sensory motor controls and cardiovascular correlation. Acta Astronautica 2018;63:745-57.
4. Oman CM, Lichtenberg BK, Money KE, McCoy RK. M.I.T./Canadian vestibular experiments on the spacetlab-1 mission: 4. Space motion sickness: Symptoms, stimuli and predictability. Exp Brain Res 1986;64:316-34.
5. Oman CM, Lichtenberg BK, Money KE. Space motion sickness monitoring experiment: Spacelab 1. In: Crampton GH, editor. Motion and Space Motion Sickness. Boca Raton, Florida, USA: CRC Press; 1990. p. 217-46.
6. Clément G, Reschke MF. In: Clément G, Reschke MF (editors). Neuroscience in Space, Chapter 1: Space Neuroscience: What is it? New York: Springer; 2008. p. 1-21.
7. Clément G, Reschke MF. In: Clément G, Reschke MF (editors). Neuroscience in Space, Chapter 4: Sensory functions in space. New York: Springer; 2008. p. 101-32.
8. Davis JR, Jennings RT, Beck BG. Comparison of treatment strategies for space motion sickness. Acta Astronautica 1993;29:587-91.
9. Thornton WE, Hoffer GW, Rummel JA. Anthropometric changes and fluid shifts. In: Johnston RS, Dietlein LF, editors. Biomedical Results from Skylab. Washington DC: US Government Printing Office; 1977. p. 330-8. (NASA Spec. Rep. SP-377).
10. Reschke MF, Bloomberg JJ, Harm DL, Paloski WH, Layne C, McDonald V. Posture, locomotion, spacial orientation, and motion sickness as a function of space flight. Brain Res Rev 1998;28:102-17.
11. Lackner JR, Graybiel A. Etiological factors in space motion sickness. Aviat Space Environ Med 1983;54:675-81.
12. Heer M, Paloski WH. Space motion sickness: Incidence, etiology, and countermeasures. Auton Neurosci 2006;129:77-9.
13. Buckey JC. Space Physiology. Oxford, New York; Oxford University Press, 2006. p. 120-36.
14. Baker ES, Barratt MR, Wear ML. Human response to space flight. In: Barratt MK, Pool SL, editors. Principles of Clinical Medicine for Space Flight. Chapter 2, Human response to space flight 1st ed. New York: Springer; 2008. p. 27-57.
15. West JB. Historical perspectives: Physiology in microgravity. J Appl Physiol 2000;89:379-84.
16. Blomqvist CG, Stone HL. Cardiovascular adjustments to gravitational stress. In: Handbook of Physiology: Section 2: The Cardiovascular System Volume III, Parts 1 and 2: Peripheral Circulation and Organ Blood Flow. Bethesda, MD: Am Physiol Society; 1983. p. 1025-63.
17. Johnson PC, Driscoll TB, LeBlanc AD. Blood volume changes. In: Johnson RS, Dietlein LF, editors. Biomedical Results from Skylab. Washington, DC: NASA Spec Rep SP-733; 1977. p. 235-41.
18. Fritsch-Yelle JM, Charles J, Jones MM, Wood ML. Microgravity decreases heart rate and arterial pressure in humans. J Appl Physiology 1996;80:910-4.
19. Parker DE, Reschke MF, Arrott AP, Homick JL, Lichtenberg BK. Otolith tilt-translation reinterpretation following prolonged weightlessness: Implications for preflight training. Aviat Space Environ Med 1985;56:601-6.
20. Young LR, Oman CM, Watt DG, Money KE, Lichtenberg BK. Spatial orientation in weightlessness and readaptation to Earth’s gravity. Science 1984;225:205-8.
21. Baumgarten R. General remarks on the role of the vestibular system in weightlessness. Arch Otorhinolaryngol 1987,244:135-42.
22. Graybiel A. General remarks on the role of the vestibular system in weightlessness. Acta Astronautica 1981;8:1015-8.
23. Wood CD, Graybiel A. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions. Aerosp Med 1968;39:1341-4.
24. Wood CD, Manno JE, Manno BR, Redetzki HM, Wood M, Vekovius WA. Side effects of antimotion sickness drugs. Aviat Space Environ Med 1985;55:1-26.
25. Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness: An update. Brain Res Bull 1998;47:395-406.
26. Cheung B, Nakashima AM, Hofer KD. Various anti-motion sickness drugs and core body temperature changes. Aviat Space Environ Med 2011;82:409-15.
27. Santos M. The development and evaluation of an intranasal scopolamine for space motion sickness. PhD Thesis. UK: King’s College London; 2006
28. Benson AJ. Motion sickness. In: Ernsting J, Nicholson AN, Rainford DS, editors. Aviation Medicine. Oxford, UK: Butterworth Ltd.; 1999. p. 455-71. Available from: https://trove.nla.gov.au/work/13766758?q&versionId=46583653. [Last accessed on Apr 23].
29. Weerts AP, Putcha L, Hoag SW, Hallgren H, Omergen AV, Van de Heyning PH, et al. Intranasal scopolamine affects the semicircular canals centrally and peripherally. J Appl Physiol 2015;119:213-8.
30. Russomano T, dos Santos MA, Andre L, de Azevedo DF, Porto F, Martinelli LK. A avaliação da interação de uma dieta controlada com a scopolamina na prevenção da desorientação espacial. Sci Med 2004;14:317-23.
31. Available from: www.techbriefs.com/component/content/article/tb/techbriefs/bio-medical/22417. [Last accessed on Apr 23].
32. Gandia P, Saivin S, Le Traon AP, Guell A, Houin G. Influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers. J Clin Pharmacol 2006;46:1008-16.
33. Mc Donough JA, Persyn JT, Nino JA, Dixon H, Boland EJ, Wang Z, et al. Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: A motion sickness medication. J Microencapsul 2007;24:109-16.